Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2016. Fulvestrant purchased from Selleck.

  • A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXTVlZmOS5|LUGwNFAhdk1? MonjOFghcA>? MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWfDRlZtOjR7N{myPVQ>
MCF-7/LTED M{TieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\3dVEvOy1zMECwJI5O NHe3epk1QCCq NWnVOWpKcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml3SNlQ6Pzl{OUS=
HCC1428 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzCU2lROS5|LUGwNFAhdk1? MUW0PEBp Mn;VbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYOxWoJTOjR7N{myPVQ>
HCC1428/LTED MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixMlMuOTByMDDuUS=> MonpOFghcA>? NFLLfJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2ficVI1QTd7Mkm0
LCC1 MWPGeY5kfGmxbjDBd5NigQ>? Ml;pNVAxKG6P NHTLTo81QC1zNESgbC=> M4TYRYFkfGm4YYTld{BWWFJic3nncoFtcW6p NWDuRlJFOjR6NUiyO|c>
LCC9 M1fpWGZ2dmO2aX;uJGF{e2G7 M{D0fFExOCCwTR?= MXG0PE0yPDRiaB?= NEXP[lZi[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= Mn;GNlQ5PTh{N{e=
MCF-7  NH3mVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHxNpJNOTByIH7N M2fWZ|Uh\A>? MU\pcohq[mm2czDj[YxtKGe{b4f0bEB1dyBzMP-8iS=> MYCyOFgyQTV3MB?=
mesangial  NY\qZlllTnWwY4Tpc44hSXO|YYm= Ml\NNE4yNTFyMDDuUS=> NWf0TGc5PDhiaB?= MkPSd5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgeJlx\SCLVjDjc4xt[Wenbh?= M2XpelI1Pzl|NkO5
Mesangial NHHVUXFHfW6ldHnvckBCe3OjeR?= MV6wMlEuOTByIH7N NFTmPYQxNjViaB?= M1joTIlvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDTcYFlOiCyaH;zdIhwenmuYYTpc44hfmmjIFfQSXI> M3qwRVI1Pzl|NkO5
ER+ MCF-7/2a Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPFTWM2OD1yLkCwOEDPxE1? M1y1e|E2OzJ2OEi0
ER+ MCF-7 NXHW[lB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j5clIxOCCq MlHVTWM2OD1yLkKxJI5O MYKxOVMzPDh6NB?=
MCF-7  MVfGeY5kfGmxbjDBd5NigQ>? MUCxNOKhdk4EoB?= NVjhOW97PzJiaB?= MUTy[ZZmenOnczD0bIUh\XO2cn;n[Y4h\W[oZXP0LGlEPTBiMT65JOOYKDFy4pkSPUBOMQ>? M2HydFI1QTB6NkWy
MCF-7  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLHW25KSzVywrDv[kBieHC{b4jpcYF1\Wy7IEKgcm0> MmLCNlM1PDh|NE[=
H1975  M13rW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGzxsDPxE1? NHXVOVAyKG1? M2PL[Ilv[3KnYYPld{B1cGViZ3XmbZRqdmmkIIPlcpNqfGm4aYT5JI9nKEhzOUe1JINmdGy|wrC= M3;lVlI1OjZ6OEGw
H1975 MXHGeY5kfGmxbjDBd5NigQ>? M3uwZVPDqM7:TR?= NITKWW0yKG1? NXqyN3A2fXC{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGxmfC15Yx?= MX:yOFI3QDhzMB?=
MCF-7  NYG1ZlcyTnWwY4Tpc44hSXO|YYm= NWH6[o5IOTBy4pEJcm3DqA>? NV\jU5lIPzJiaB?= MVLy[ZZmenOnczD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZiRUNCpIlvKGOnbHygbY53[XOrb36= NFvLfHQzOzl|Nke3Ny=>
MCF-7  MXjGeY5kfGmxbjDBd5NigQ>? MmHHNVAx6oDLbl5CpC=> MUKyOE81QCCq M1fUTIZi[2muaYTheIV{KGmwdnHzbY9vKHSqcn;1[4ghVU2SczegcY9lfWyjdHnvci=> NV[0UWpFOjN7M{[3O|M>
BT474-tet-shMED1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL2cIMxNjFvNTFOwG0> MmL2O{Bl MX;pcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4fTblI{QTN4MkO0
ZR75-1-tet-shMED1  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm4NE4yNTVizszN MmDkO{Bl NHLxdo5qdmO{ZXHz[ZMhM0SxeDDpcoR2[2WmIHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYOyN|k{PjJ|NB?=
MCF-7-tet-shMED1 M2q3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3jN24xNjFvNTFOwG0> M17RSlch\A>? MULpcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVGyN|k{PjJ|NB?=
HepG2  MVzGeY5kfGmxbjDBd5NigQ>? NXXZdWpZOC5yMT2xNEDPxE1? NYrXUmF5OThiaNMg NHP2T4di[3SrdnH0[ZMhfGinIFXSSU1u\WSrYYTl[EB1emGwc3PybZB1cW:wIH;mJGFHOkWU NXXZbIl7OjN5M{OxPFg>
MCF-7L  MWfGeY5kfGmxbjDBd5NigQ>? NEjKcocyODBibl5CpC=> NXK4WGE{OTBibXnuM|I1KGhxNEigbC=> NGTwOGlz\XO3bITzJIlvKEWJRmKsJGhGWjJiYX7kJGhGWjNicHjvd5Bpd3K7bHH0bY9vKGG2IIDyc4xwdmenZDDlfJBwe3W{ZR?= NVj6PHBDOjN4OE[0NVY>
MCF-7L  M1O5NmZ2dmO2aX;uJGF{e2G7 MmOxNVAxKG6PwrC= NWriUodUPDhiaB?= MlvibY5lfWOnczD1dJJm\3WuYYTpc44hd2ZibWLORUBw\iCHR1\SJIxq\2GwZDDIRk1GT0Z? NFXPcW8zOzZ6NkSxOi=>
MCF-7L NHjCR3RHfW6ldHnvckBCe3OjeR?= Mne1NVAxKG6PwrC= NHe1[Gg1QCCq MoDYbY5lfWOnczDFS2ZTKG[jbXnsfUBu\W2kZYKgZYN1cX[jdHnvckBz\XG3aYLl[EBGWg>? MWWyN|Y5PjRzNh?=
C4-12  MVvGeY5kfGmxbjDBd5NigQ>? MnPpNVAxKG6PwrC= M3nRfVQ5KGh? MUXpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT MnPoNlM3QDZ2MU[=
MCF-7L M2rid2Z2dmO2aX;uJGF{e2G7 NXz2SnEzOTByIH7NxsA> M{iyOlI1KGh? Mo\CbY5lfWOnczDFS2ZTKHCqb4PwbI9zgWyjdHnvckBz\XG3aYLl[EBJSi2HR1[g[pVv[3Srb36= NEfmXZMzOzZ6NkSxOi=>
MMQ  M1fl[2Z2dmO2aX;uJGF{e2G7 MmHqNE03OjVibl2= NETISIk4OiCq NFTMb29ld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDld5Rzd2enbjDy[YNmeHSxcj5OtUApTVMQsTm= NIO5[WwzOzV{M{O1Oy=>
H1975  M4r2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmwMlMyOjVvMUCg{txO M136SVYh\A>? NFHhO45qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{HCeFI{Ozl7OUW3
H1975  NWDDN5A6SXCxcITvd4l{KEG|c3H5 NXP2XJVYOjByIH7N MkHOO|IhcA>? Mofx[Y5p[W6lZYOg[ZJtd3SrbnniJIlv\HWlZXSgZZBweHSxc3nz MlrGNlM{QTl7NUe=
MCF-7  NFy3XWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqxNE8yODBxMUCwNEBvVQ>? NIXCVlUzNzRxNjDk M3W1cWROW09? NXTHO|RbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NU\CS41ROjN|MUO1NFY>
MCF-7  M{n4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLM[5FNOTByIH7N NU\vbY1YPCCm NF[ybXVFVVOR MmrlbY5lfWOnczDhJIhq\2incjDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKHSqZTDHNUBxcGG|ZdMg NGfZc|IzOzNzM{WwOi=>
MLO-Y4  NYX6Ro1jTnWwY4Tpc44hSXO|YYm= MUOxxsDPxE1? NIDZTYsyKGh? MWLpcohq[mm2czDFNk1qdmS3Y3XkJGN5PDNiZYjwdoV{e2mxbh?= MVuyN|I1PzB3Nx?=
MCF-7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxNFAhdk1? MnTXOFghcA>? M1;MU4Fjem:pYYTld{B1cGVicILvcIln\XKjdHn2[UBm\m[nY4Sgc4YhdW:mZYLheIUhdmm2cn;zZZRqfmVic4Ty[ZN{ M2ewXVI{OjF4N{S0
TG1-1  NETCdIZHfW6ldHnvckBCe3OjeR?= NUnvSWc1OcLizszN M37NeVI1KGh? M{HaeoFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> NVOzbod1OjNyOEi2NFc>
TG1-1  M2nCXmZ2dmO2aX;uJGF{e2G7 NWqxV4xSOcLizszN M{HSZ|I1KGh? MYnhZpJw\2G2ZYOgSVLDqGmwZIXj[YQh[WOldX31cIF1cW:wIH;mJHBKO0t? MV[yN|A5QDZyNx?=
MCF7 NH;QS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj3NVAxKG6P NGnxPHA1QCCq M{PXXYxm[WS|IITvJIEhe2mvaXzhdkBtd3O|IHnuJJN2en[rdnHsJIF{KHerdHig[I95d3K3YnnjbY4h[WyxbnW= NVLoeZFvOjNyN{eyOFk>
MCF7 NW\DSmZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYixNFAhdk1? M321PVQ5KGh? NX;tSYoy\W6qYX7j[ZMhdnW2bHnuMY1m\GmjdHXkJINmdGxiZHXheIg> NVW2T45GOjNyN{eyOFk>
MCF-7  NWLi[VE6TnWwY4Tpc44hSXO|YYm= MVG2JIg> NFfSZWVFVVOR MXjheJRmdnWjdHXzJJRp\SCobIXkbY95d26rbD2gc5Ih\mWwaHX4ZY1q\C2rbnT1Z4VlKGmwY4LlZZNmKGmwIH3pVk0zOSCneIDy[ZN{cW:w Mn7ZNlMxPTJyM{[=
MCF-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTNc5kyODBibl2vNUDPxE1? NHjWSHI2KGR? MljqbY5pcWKrdIOgeIhmKHO2aX31cIF1cW:wIH;mJFE4|rJvZYP0doFlcW:u NU\TUYRJOjJ7OEK3OlU>
MCF-7 NX3JSoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNFAhdk1? M3Lt[|Uh\A>? MYnpcohq[mm2czD0bIUhe3SrbYXsZZRqd25ib3[g[pV{[XKrZXzpckBJ M3;2R|IzQTh{N{[1
1471.1 M4qyZWZ2dmO2aX;uJGF{e2G7 NGXyVFEyODBibl2= NHr1dmIyKGh? NHvQ[2xGfE:KwrC= NGXrO2d1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NIP4fHAzOjh4OUGwOi=>
MCF-7 M4\kOmZ2dmO2aX;uJGF{e2G7 M4rNflExOCCwTR?= M4j1XFEhcA>? Mo\4SZRQUMLi MX;0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= Mk\BNlI5PjlzME[=
HeLa MojaSpVv[3Srb36gRZN{[Xl? NE\IdoQyODBibl2= MXexJIg> M1nGWmV1V0kEoB?= MUH0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= Mkj2NlI5PjlzME[=
COS-7  Mmf4SpVv[3Srb36gRZN{[Xl? MV6xNFAhdk1? M4nLRVEhcA>? MnG0SZRQUMLi M162OpRic2W|IH;uJIEheHWwY4TheIUhe3SjaX7pcocheGG2dHXyci=> Mn\DNlI5PjlzME[=
BG1L-OHTLT  NV;WTFEzTnWwY4Tpc44hSXO|YYm= NUW1ZmF7OTEEoH7N NFnLRVUzPMLiaNMg M{TBSolvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= NIfGRW8zOjZ3MkW1PC=>
BG1L-ICILT NHuzPXpHfW6ldHnvckBCe3OjeR?= MkLjNVDDqG6P NVjJWnhDOjUEoHlCpC=> M1LSTolvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= NX3IbGNmOjJ4NUK1OVg>
PC-9 NVTDTolvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfOfXVWOC5yMEOtN|Ah|ryP NYTxSlY2PDhiaB?= NFS0[FJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVKyNlU3ODZ|NB?=
H1650 NF;ldZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[wMlAxOy1|MDFOwG0> M3nOWFQ5KGh? NVyyOolicW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYqyNlU3ODZ|NB?=
H1975 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMlAxOy1|MDFOwG0> NUnUXJB5PDhiaB?= MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUDKSYlFOjJ3NkC2N|Q>
H1975 NHTwPZhHfW6ldHnvckBCe3OjeR?= MkPHN:Kh|ryP NFrTN3E{KGh? NIfnUphi[nKxZ3H0[ZMhfGinIIDoc5NxcG9vRVfGVkBqdmS3Y4Tpc44h[nliZYP0do9o\W5? MlTRNlI2PjB4M{S=
H1975 MmHTSpVv[3Srb36gRZN{[Xl? M3vqVlPDqM7:TR?= NHnsZ4k4KGR? MYrpcoR2[2W|IFXHSnIh\XiycnXzd4lwdg>? NESxVWUzOjV4ME[zOC=>
HTR-8 NFHkSotHfW6ldHnvckBCe3OjeR?= MnXjNeKh|ryP MlHaNU01QCCq Mn3S[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSVfGRnA4KG2UTlG= MlHNNlI{QDNzMUG=
JEG-3 NHrXRWZHfW6ldHnvckBCe3OjeR?= MVuxxsDPxE1? NYDIcnVvOS12ODDo MlXm[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSVfGRnA4KG2UTlG= M4W2VlIzOzh|MUGx
Huh7 M{nHNWZ2dmO2aX;uJGF{e2G7 NFWyfZo2OMLizszN Mnr4OFghcA>? MlTibY5pcWKrdIOg[4VvcXO2ZXnuMY1m\GmjdHXkJHBQVjFidILhcpNi[3SrdnH0bY9v Ml7INlI{ODR{OU[=
201T MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPGOUDPxE1? MVO3NkBp NV;4S5Q1cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= NV3VdVlHOjJ{NUi0O|Y>
A549  NWXZOG8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:1JO69VQ>? NIWzWW04OiCq Mk[2bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKH[jbnTleIFvcWJ? MX6yNlI2QDR5Nh?=
MCF-7 M1fVV2Z2dmO2aX;uJGF{e2G7 MlXpNeKh|ryP NILwT4UzPCCqwrC= NGXJXplld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? NX;xTnN{OjJyNEmzNVY>
HCC-1428 NFLz[IJHfW6ldHnvckBCe3OjeR?= MVexxsDPxE1? NIHKOpYzPCCqwrC= M{\Ye4Rwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? MWSyNlA1QTNzNh?=
MDA-361 NUS0eY5oTnWwY4Tpc44hSXO|YYm= NULCeVI6OcLizszN MlO4NlQhcMLi Mn7n[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh MXKyNlA1QTNzNh?=
ZR75-1 NYSycnVFTnWwY4Tpc44hSXO|YYm= Mn;6NeKh|ryP MkTuNlQhcMLi MXjkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb36gbY5lfWOnZDDifUA1NU:KLWSgxsA> MWeyNlA1QTNzNh?=
MCF-7 NIL1[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7jNlVYOcLizszN MmXHOU0yOCCm NVi4OYdje3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w M4TH[VIzODR7M{G2
HCC-1428 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHnVY0yyqEQvF2= MoS1OU0yOCCm M4TCdZN2eHC{ZYPz[ZMhTTJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>? MVqyNlA1QTNzNh?=
MDA-361 NWP3[nNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxxsDPxE1? MYq1MVExKGR? MkLNd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v NF\pbpUzOjB2OUOxOi=>
ZR75-1 NIqzRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWxNeKh|ryP NHPVNJo2NTFyIHS= M4fsTpN2eHC{ZYPz[ZMhTTJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>? MXmyNlA1QTNzNh?=
MCF-7/AC-1 M4rTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzyOmYxNTBwMjFOwG0> MUC2JIQ> Ml7KbY5pcWKrdIOgZ4VtdCCpcn;3eIghdW:mZYP0cJk> Mn7UNlIxPDJ5OUK=
MCF7 NWj4Z|BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zDR|ExKML3TR?= NYrQSmRNPDhiaB?= MlzUbY5lfWOnczDj[YxtKGmwaHnibZRqd25id3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KG[rYoLvZoxie3S| NGq0PHMzOjB2MUi4Oy=>
MMQ M{\RdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMVYzPSCwTR?= NI\sSoE4OiCq M3;GXZBzd2S3Y3XzJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd28EoB?= NGDHelUzOjBzNUGwNS=>
MMQ M3TkbmZ2dmO2aX;uJGF{e2G7 M33BNFAuPjJ3IH7N MXy3NkBp MWTwdo9lfWOnczDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSsJIRwe2VvZHXw[Y5l\W62IILl[JVkfGmxbjDpckBRWkxic3XjdoV1cW:w NHjpb2czOjBzNUGwNS=>
MCF7 NXGzeFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjqbowxNTFizszN M3;4dVI1NTF{MDDo MVjpcohq[mm2czD0bIUh\3Kxd4ToJI9nKE2FRketXWIuOcLi NE\SRW8zOTh4M{K1PC=>
HepG2 M4jHemFxd3C2b4Ppd{BCe3OjeR?= NUfyPGVnOC5zwrFOwG0> MnvLNlQhcA>? NYLybJFR[WKxbHnzbIV{KHSqZTDld5Rzd2enbj3pcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZiYYDvRWkh[W6mIHHwc20> MmDDNlE5OTZ{M{O=
MCF7–iFR3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrwdVQ5OjBvMUCwJI5O MknUPVYhcA>? NXG0TGtZ\W6qYX7j[ZMhSVBvaX7keYNm\CClZXzsJIdzd3e2aDDpcohq[mm2aX;u MWWyNVc6Ojh6OR?=
MCF7S M{\PO2Z2dmO2aX;uJGF{e2G7 M3;j[|HDqM7:TR?= NVzR[HVIPDhiaB?= NEXxNmxld3ewcnXneYxifGW|IH;2[ZJidGxiRWNOtUBxem:2ZXnuJIxmfmWucx?= MXGyNVU{OzF7NR?=
MCF7 MX;GeY5kfGmxbjDBd5NigQ>? NUH5UGU{OcLizszN M3i4T|Q5KGh? NFrqRo5ld3ewcnXneYxifGW|IH;2[ZJidGxiRWNOtUBxem:2ZXnuJIxmfmWucx?= NYnZd4lrOjF3M{OxPVU>
MCF7S Mn62SpVv[3Srb36gRZN{[Xl? M4KzdFHDqM7:TR?= M1jLTFch\A>? NWfidGFV[XS2ZX71ZZRmeyC2dX3vdpNxcGW{ZTDmc5Ju[XSrb36gZY5lKHC{b3zp[oVz[XSrb36= MlrxNlE2OzNzOUW=
MCF7S MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHlcGMxNjVxMTFOwG0> M3H2PFch\A>? NGfRPZRFVVOR NXjTRYxi\GWlcnXhd4V{KGOnbHyg[Zhx[W6|aX;u M1\0NVIyPTN|MUm1
T47D  MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr3O2Q1KG6P NFTSW|Y1OCCq M2XnbZN2eHC{ZYPz[ZMh[2WubDDndo94fGhibX;k[ZJifGWueR?= M2XUe|IyPDhyM{mx
BT474  NIrFRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jXblQhdk1? M4PjR|QxKGh? NYfXfVB7e3WycILld5NmeyClZXzsJIdzd3e2aDDtc4RmemG2ZXz5 NGPofIYzOTR6MEO5NS=>
T47D  Ml;sSpVv[3Srb36gRZN{[Xl? MkXhNVAhdk1? M3fNZ|QxKGh? NWflcWpH\G:5boLl[5Vt[XSnczDFVu6yKHC{b4TlbY4> MYeyNVQ5ODN7MR?=
BT474  M2HmTmZ2dmO2aX;uJGF{e2G7 M2H1b|ExKG6P M4fkNlQxKGh? Ml\t[I94dnKnZ4XsZZRmeyCHUt8xJJBzd3SnaX6= MUWyNVQ5ODN7MR?=
MCF7 M4\PdWZ2dmO2aX;uJGF{e2G7 M33WclExOCCwTR?= M4WyXFch\A>? MoD1doVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NVThc5lVOjF|OU[wPVQ>
T47D  MVvGeY5kfGmxbjDBd5NigQ>? NUXZO|lwOTByIH7N NG\5fY44KGR? MV;y[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 M1zJRlIyOzl4MEm0
BT474  M2rCWmZ2dmO2aX;uJGF{e2G7 MlPONVAxKG6P MkjHO{Bl M2DvepJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> M3\XdlIyOzl4MEm0
MDAMB361 M3fWbGZ2dmO2aX;uJGF{e2G7 M2nDUVExOCCwTR?= MmTiO{Bl MVHy[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 M3vCflIyOzl4MEm0
MCF7 NHW0NXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ThfVAvODFvMTFOwG0> MoHiO{Bl Moj3doVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MmfQNlE{QTZyOUS=
T47D  M4[1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlAyNTFizszN MX23JIQ> NWTzU|d[emWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 M1n5NVIyOzl4MEm0
BT474  MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6wMlAyNTFizszN NXXyUZJLPyCm MXPy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? Mn65NlE{QTZyOUS=
MDAMB361 M{PUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMlAyNTFizszN MWW3JIQ> NF;wV2Vz\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= MlX5NlE{QTZyOUS=
MCF7 NUGxOnBTTnWwY4Tpc44hSXO|YYm= MXqxNFAhdk1? NXL2bYE6PyCm MXzpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p MmLDNlE{QTZyOUS=
T47D  NHTrcVlHfW6ldHnvckBCe3OjeR?= MYmxNFAhdk1? NGPrOlY4KGR? NGXQXIxqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n MoDZNlE{QTZyOUS=
BT474  NUTJbIxTTnWwY4Tpc44hSXO|YYm= NHvXXnEyODBibl2= M2LDRVch\A>? MlPSbY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= M1e2ZVIyOzl4MEm0
MDAMB361 NXXsS5dJTnWwY4Tpc44hSXO|YYm= MnXNNVAxKG6P MUi3JIQ> NG\SSZpqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n M1fnPFIyOzl4MEm0
MCF7 NHqwRlVHfW6ldHnvckBCe3OjeR?= M2PxdlExKG6P M4HydVk3KGh? MWfkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> NXfPcGRPOjF|N{izN|M>
MDA-MB-231 NH7FbWdHfW6ldHnvckBCe3OjeR?= M4fUfVExKG6P MXi5OkBp MmT2[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> MlToNlE{Pzh|M{O=
SK-BR-3 MXfGeY5kfGmxbjDBd5NigQ>? M4HvT|ExKG6P MYC5OkBp Mo[z[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> M17KdlIyOzd6M{Oz
MCF-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrl[lMyODBibl2= NHHWfXQ4Oi97NjDo M37HToNifXOnczDj[YxtKGO7Y3zlJIFzemW|dB?= Mn6xNlEzQTl6NkK=
MMQ M{f0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3IdY4xNjByOD22NlUhdk1? MVK3NkBp M3TYc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWnkVZFzOjB5MEC3OVU>
MMQ Mnf4SpVv[3Srb36gRZN{[Xl? M2nhXlAvODB6LU[yOUBvVQ>? MXS3NkBp NH;UfnBqdmirYnn0d{BRWkxic3XjdoV1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHmyRW8zODdyMEe1OS=>
MMQ NFjvcnNHfW6ldHnvckBCe3OjeR?= MoPnNE4xPC14MkWgcm0> M2XLVFczKGh? Ml7EbY5pcWKrdIOgSXLPuSCneIDy[ZN{cW:w M1XLVlIxPzByN{W1
MMQ NH3keGxHfW6ldHnvckBCe3OjeR?= M{TYWVAvODRvNkK1JI5O NXyyb5BUPzJiaB?= MmqweZBz\We3bHH0[ZMhXEeIzsKzJIFv\CCWR1dOtnJKUSCneIDy[ZN{cW:w MWKyNFcxODd3NR?=

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5% DMSO+95% Corn oil
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01797120 Active, not recruiting Metastatic Breast Cancer PrECOG, LLC.|Novartis May 31, 2013 Phase 2
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT03024580 Not yet recruiting Breast Neoplasm Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute March 2017 Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3
NCT02983604 Recruiting Advanced Estrogen Receptor Positive HER2- Breast Cancer Gilead Sciences January 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID